Bay 27-9955

Bay 27-9955 is an orally active, small molecule glucagon receptor antagonist developed by Bayer for the treatment of Type 2 diabetes mellitus. It functions by selectively binding to the glucagon receptor (GCGR), thereby inhibiting glucagon-stimulated hepatic glucose production and lowering blood glucose levels. In early clinical trials, Bay 27-9955 demonstrated the ability to significantly blunt the hyperglycemic effects of exogenous glucagon in healthy volunteers and patients, suggesting its potential to address the fasting hyperglycemia associated with excessive glucagon action in diabetic states. However, development of this specific compound was discontinued in favor of other candidates.